GlaxoSmithKline are currently testing a new drug for cervical cancer patients...
...which shows great immune response in women aged 15 to 55.
Drug maker, GlaxoSmithKline announced today they are developing an experimental cervical cancer vaccine which creates immune response in all women aged between 15 to 55 during a study.
The new drug dubbed, Cervarix, is intended to build the immune system against human papilloma virus (HPV), which is most often associated with cervical cancer.
The study is now in its third phase is being carried out on 666 women. All volunteers were injected with Cervarix. Seven months after the injecting, all patients had developed immune responses to the two HPV viruses.
The studies authors believe Cervarix can protect women against cervical cancer infections for a period of four to five years. Reportedly the study did not find any dangerous side effects from the vaccine.
Drug maker, GlaxoSmithKline announced today they are developing an experimental cervical cancer vaccine which creates immune response in all women aged between 15 to 55 during a study.
The new drug dubbed, Cervarix, is intended to build the immune system against human papilloma virus (HPV), which is most often associated with cervical cancer.
The study is now in its third phase is being carried out on 666 women. All volunteers were injected with Cervarix. Seven months after the injecting, all patients had developed immune responses to the two HPV viruses.
The studies authors believe Cervarix can protect women against cervical cancer infections for a period of four to five years. Reportedly the study did not find any dangerous side effects from the vaccine.
Comments